About Large ribosomal subunit protein uL4
Large ribosomal subunit protein uL4 (RPL4) is a protein
from Homo sapiens identified by UniProt accession
P36578, 427 residues long.
MolForge cross-references it against 0 known binders and
93 disease associations.
Target properties
| Protein name | Large ribosomal subunit protein uL4 |
| UniProt accession | P36578 |
| Gene | RPL4 |
| Organism | Homo sapiens |
| Length | 427 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (93)
Diseases linked to this target (Open Targets).
- Duchenne muscular dystrophy · score 0.50
- cystic fibrosis · score 0.50
- influenza · score 0.46
- Becker muscular dystrophy · score 0.29
- clear cell renal carcinoma · score 0.27
- endometrial cancer · score 0.27
- qualitative or quantitative defects of dystrophin · score 0.26
- acute myeloid leukemia · score 0.22
- thyroid gland adenocarcinoma · score 0.18
- hypertension · score 0.13
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P36578-F1 | alphafold | PREDICTED | 87.11 | — |
Amino-acid sequence (427 residues)
MACARPLISV YSEKGESSGK NVTLPAVFKA PIRPDIVNFV HTNLRKNNRQ PYAVSELAGH QTSAESWGTG RAVARIPRVR GGGTHRSGQG AFGNMCRGGR MFAPTKTWRR WHRRVNTTQK RYAICSALAA SALPALVMSK GHRIEEVPEL PLVVEDKVEG YKKTKEAVLL LKKLKAWNDI KKVYASQRMR AGKGKMRNRR RIQRRGPCII YNEDNGIIKA FRNIPGITLL NVSKLNILKL APGGHVGRFC IWTESAFRKL DELYGTWRKA ASLKSNYNLP MHKMINTDLS RILKSPEIQR ALRAPRKKIH RRVLKKNPLK NLRIMLKLNP YAKTMRRNTI LRQARNHKLR VDKAAAAAAA LQAKSDEKAA VAGKKPVVGK KGKKAAVGVK KQKKPLVGKK AAATKKPAPE KKPAEKKPTT EEKKPAA
Explore Large ribosomal subunit protein uL4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets